Murray Yule
Pharmaceutical Sciences
Allergan
Norway
Biography
Murray Yule joined BerGenBio in 2011 and serves as Clinical Development Officer. Since 1998, he has gained extensive experience in oncology clinical development supervising multiple early phase clinical studies of novel anticancer products, as well as planning and executing global development strategies for several anticancer drugs for top-ten pharmaceutical companies. His work has led to licensing approvals for novel tubulin binders in solid tumors and epigenetic therapies in acute leukemia. He completed his medical training in oncology at Addenbrookes Hospital, Cambridge and holds a PhD in experimental pharmacology.
Research Interest
Science and Business
